Remagine Labs Overview
- Year Founded
-
2001
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Later Stage VC
- Investors
-
10
Remagine Labs General Information
Description
Developer of wearable drug delivery systems designed for epilepsy treatment. The company's system offers a non-invasive and controlled method of delivering epilepsy medication, reducing the risk of missed doses and side effects, enabling patients to manage their condition more effectively, improving quality of life, and reducing the economic burden associated with epilepsy.
Contact Information
Website
www.remaginelabs.comCorporate Office
- Austin, TX
- United States
Corporate Office
- Austin, TX
- United States
Remagine Labs Timeline
Remagine Labs Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 16-Sep-2026 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 01-Jul-2025 | Completed | Startup | |||
| 3. Grant | 01-Jul-2024 | Completed | Startup | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Grant | $3M | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Remagine Labs Patents
Remagine Labs Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025111664-A1 | Transdermal drug delivery compositions | Inactive | 30-Nov-2023 | ||
| US-20260306827-A1 | Iontophoresis pharmaceutical delivery system | Pending | 25-May-2023 | ||
| WO-2024239072-A1 | Iontophoresis pharmaceutical delivery system | Inactive | 25-May-2023 | A61N1/325 |
Remagine Labs Signals
Remagine Labs Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Monash Investment Holdings | University | Minority | ||
| Praxis (Drug Discovery) | Corporation | Minority | ||
| Breakthrough Victoria | Venture Capital | Minority | ||
| Genesis Pre-Seed Fund | Venture Capital | Minority | ||
| Monash University | University | Minority |
Remagine Labs FAQs
-
When was Remagine Labs founded?
Remagine Labs was founded in 2001.
-
Where is Remagine Labs headquartered?
Remagine Labs is headquartered in Austin, TX.
-
What is the size of Remagine Labs?
Remagine Labs has 7 total employees.
-
What industry is Remagine Labs in?
Remagine Labs’s primary industry is Therapeutic Devices.
-
Is Remagine Labs a private or public company?
Remagine Labs is a Private company.
-
What is Remagine Labs’s current revenue?
The current revenue for Remagine Labs is .
-
How much funding has Remagine Labs raised over time?
Remagine Labs has raised $500K.
-
Who are Remagine Labs’s investors?
Monash Investment Holdings, Praxis (Drug Discovery), Breakthrough Victoria, Genesis Pre-Seed Fund, and Monash University are 5 of 10 investors who have invested in Remagine Labs.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process